Wednesday, August 5, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
Policy & Regulation

EU AI Act transparency obligations apply today, high-risk obligations deferred to December 2027

On 2 August 2026, EU AI Act transparency obligations under Article 50 became applicable, requiring emotion-recognition and biometric-categorisation systems to notify natural persons exposed to them. The high-risk obligation suite under Annex III, including conformity assessment and human oversight, was deferred to 2 December 2027 by the Digital Omnibus (Regulation EU 2026/1744) adopted by the Council on 29 June and in force since 27 July 2026. Most compliance framings are conflating the two.

Aug 2, 2026 · 7 min read

Market Moves

Delian Capital partner warns of a Chinese BCI bubble

VCBeat, the Chinese healthcare-investment media outlet, published an on-record investor take on the Chinese brain-computer interface sector on 2 August 2026. Delian Capital partner Jiang Donghui framed the sector as at risk of a bubble cycle before maturity, laid out a four-quadrant investment matrix based on demand and technological advancement, and named Chinese BCI companies across invasive, semi-invasive and non-invasive paths. H1 2026 financing alone accounted for approximately 60 per cent of the sector's thirteen-year total.

Aug 2 · 6 min read

Industry News

Chinese BCI programmes produced four tangible results in July

In one month, four separate Chinese brain-computer interface programmes each produced a public result. Neuracle wrote the world's first commercial prescription for an invasive BCI at Huashan Hospital on 13 July. NeuroXess ran a two-patient cross-city Chinese chess demonstration between Shanghai and Nanchang. StairMed's investigational trial put three quadriplegic patients into paid remote work. And at the World AI Conference in Shanghai, a paralysed fine-arts graduate from Shenzhen demoed a mind-controlled wheelchair he had built himself with LLM-assisted DIY.

Jul 31 · 7 min read

Industry News

Science Corp hires Butterfly Network's Nevada Sanchez as engineering chief as PRIMA commercial launch begins in Germany

Science Corporation appointed Butterfly Network co-founder Nevada Sanchez as Executive Vice President of Engineering on 29 July, one week after CE mark approval for the PRIMA retinal implant. Sanchez's remit spans PRIMA, the Biohybrid neural interface, the Vessel organ-perfusion programme, and the Science Foundry MEMS fabrication line. First commercial implants are expected in Germany this fall.

Jul 29 · 5 min read

Industry News

Neuvotion launches first US commercial BCI-platform product this fall

On Monday 27 July 2026, Chad Bouton's Neuvotion announced the first US commercial launch of a product from a brain-computer interface platform. NeuStim NN-01, a wearable neuromuscular stimulator for hand recovery after stroke or C5 spinal cord injury, ships this fall. Neuvotion holds an exclusive worldwide license from the Feinstein Institutes, where Bouton is senior author of the 16 July Nature Medicine paper on the underlying double neural bypass platform. The intracortical BCI half of that platform, tested in one patient (Keith Thomas), remains investigational.

Jul 27 · 10 min read

Industry News

Precision Neuroscience appoints John Donoghue as scientific advisor

On Thursday 23 July 2026, New York-based Precision Neuroscience announced the appointment of John Donoghue - founding investigator of the BrainGate consortium at Brown, co-founder of Cyberkinetics, and inaugural director of the Wyss Center for Bio and Neuroengineering in Geneva - as a scientific advisor to the company. Donoghue will advise Precision's scientific and engineering teams on device design, signal decoding, and clinical strategy. The appointment lands two days after Precision's non-paralysed cursor-control demonstration across its 15-plus academic-medical-centre clinical network, and at exactly the moment ABILITY Neurotech, the Wyss Center spin-out whose technology was conceived under Donoghue's own directorship, prepares to begin its own chronic first-in-human implantation in ALS patients.

Jul 25 · 9 min read

Industry News

ABILITY Neurotech reaches first-in-human at TUM Munich

On Tuesday 21 July 2026, Geneva-based ABILITY Neurotech announced the first-in-human recording of its fully implantable, batteryless brain-computer interface at TUM University Hospital Rechts der Isar in Munich. The device is a 128-channel sub-scalp ECoG array with a laser-based transcutaneous optical data link streaming raw neural signals through the scalp at 50 megabits per second. The first cohort is up to five brain-tumour surgery patients recording 20 to 30 minutes of intraoperative data each. The company's separate chronic implantation trial in ALS patients at UMC Utrecht, cleared by Dutch regulators on 26 May 2026, has not yet performed a surgery.

Jul 24 · 9 min read